The rapamycin analog CCI-779 is a potent inhibitor of pancreatic cancer cell proliferation

This publication has 30 references indexed in Scilit:

• Sustained Activation of the JNK Cascade and Rapamycin-Induced Apoptosis Are Suppressed by p53/p21Cip1
  Molecular Cell, 2003
• Identification of TOR Signaling Complexes: More TORC for the Cell Growth Engine
  Cell, 2002
• Exploiting molecular targets in pancreatic cancer
  Hematology/Oncology Clinics of North America, 2002
• Linking molecular therapeutics to molecular diagnostics: Inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo
  Proceedings of the National Academy of Sciences, 2001
• The rapamycin-sensitive signal transduction pathway as a target for cancer therapy
  Oncogene, 2000
• Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation
  Biochemical Journal, 1999
• Evidence of insulin-stimulated phosphorylation and activation of the mammalian target of rapamycin mediated by a protein kinase B signaling pathway
  Proceedings of the National Academy of Sciences, 1998
• Mechanisms and consequences of activation of protein kinase B/Akt
  Current Opinion in Cell Biology, 1998
• Advances in the diagnosis and treatment of adenocarcinoma of the pancreas
  Published by Springer Nature ,1997
• RAPAMYCIN, A POTENT IMMUNOSUPPRESSIVE DRUG, CAUSES PROGRAMMED CELL DEATH IN B LYMPHOMA CELLS
  Transplantation, 1995